The University of Pennsylvania’s pioneering cell therapy physician Carl June shared new data Monday that showed the risk of secondary cancers following CAR-T therapy was very low. In over 1,500 patients treated at UPenn and Stanford University, only a small percentage had a second cancer after treatment, June reported Monday morning at a Friends of … Continue reading UPenn and Stanford analysis finds no secondary cancer cases directly due to CAR-T